Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia

1

Introduction

00:00 • 2min

2

Rituximab in B Cell All

01:33 • 2min

3

The Pharmacology of Rituxim Antibodies

03:26 • 2min

4

The Role of Antibodies in CD20 Activation

05:34 • 2min

5

The Data Supports the Use of Rituxin for ALL

07:58 • 2min

6

The Role of Rituxin in Leukemia Treatment

10:00 • 4min

7

Rotuxemab and Asparigenase Adherence

13:59 • 4min

8

The Differences Between UK 2014 and COG Protocols

17:39 • 4min

9

The Germans' Induction to CCG and COG

22:06 • 2min

10

The Differences Between Grawl and Retoxin

24:14 • 2min

11

Retuximab and the Grawl Trial

26:37 • 2min

12

The Differences in Prescription of Transplantation

28:55 • 3min

13

Retuximab: A Flaw in the Grawl Study

31:46 • 2min

14

The Ratify Effect on Event-Free Survival

33:47 • 3min

15

The Effects of Retoxin on Overall Survival

36:49 • 2min

16

Retuxemab and the EFS Benefit

39:01 • 2min

17

The Dangers of Post-Transplant Outcomes

40:32 • 2min

18

Should We Give Retuximab to Anyone With BSL, ALL?

42:04 • 2min

19

Ophatuma MAB: A Drug That Nobody Uses for Anything?

44:20 • 6min